Molecular structure of LG 100268, CAS Number: 153559-76-3
LG 100268 (CAS 153559-76-3)
See product citations (2)
Application:
LG 100268 is a potent agonist of RXR
CAS Number:
153559-76-3
Molecular Weight:
363.49
Molecular Formula:
C24H29NO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
A potent RXR agonist for evaluation in the treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM).
LG 100268 (CAS 153559-76-3) References
- The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. | Lenhard, JM., et al. 1999. Diabetologia. 42: 545-54. PMID: 10333046
- Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. | Hirase, N., et al. 1999. Oncology. 57 Suppl 2: 17-26. PMID: 10545799
- Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. | Singh Ahuja, H., et al. 2001. Mol Pharmacol. 59: 765-73. PMID: 11259621
- Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. | Liu, S., et al. 2002. Endocrinology. 143: 2880-5. PMID: 12130551
- Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. | Suh, N., et al. 2002. Clin Cancer Res. 8: 3270-5. PMID: 12374698
- The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. | Rendi, MH., et al. 2004. Cancer Res. 64: 3566-71. PMID: 15150113
- The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. | Li, Y., et al. 2007. Clin Cancer Res. 13: 6224-31. PMID: 17947490
- The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. | Liby, K., et al. 2008. Mol Cancer Ther. 7: 1251-7. PMID: 18483313
- Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. | Liby, K., et al. 2008. Clin Cancer Res. 14: 4556-63. PMID: 18628471
- Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. | Liby, K., et al. 2009. Cancer Prev Res (Phila). 2: 1050-8. PMID: 19952361
- The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. | Mazumdar, A., et al. 2012. Cancer Prev Res (Phila). 5: 1195-202. PMID: 22926341
- The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. | Cao, M., et al. 2016. Cancer Prev Res (Phila). 9: 105-14. PMID: 26554632
- Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. | Maltepe, E., et al. 1997. Nature. 386: 403-7. PMID: 9121557
- Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. | Mukherjee, R., et al. 1997. Nature. 386: 407-10. PMID: 9121558
Inhibitor of:
GREB1L, RANK, RXRβ, and TIG2.Activator of:
B42, Retinal RX, RXR alpha, RXR beta, RXR gamma, and RXRβ2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LG 100268, 5 mg | sc-211737 | 5 mg | $390.00 |